Industry Relations Council Participants

Thank You to our Industry Partners!

HOPA's Industry Relations Council (IRC) was created to offer organizations the opportunity to collaborate with HOPA to achieve our mission to advance oncology pharmacy practice by supporting hematology/oncology pharmacy practitioners in optimizing cancer patient care.

Premier Level IRC Partners

Abbvie AstraZeneca DSI Genentech GSK Johnson&Johnson Sanofi Syndax
Amgen BeOne Exelixis Gilead Incyte Pfizer Servier

Executive Level IRC Partners

Astellas BMS Ipsen Lilly Regeneron Takeda
Boehringer-Ingelheim EMD Serono Jazz Pharma Merck Taiho

Associate Level IRC Partners

Aveo Gamida Geron Novartis Stemline
Eisai Genmab Iovance Sandoz TerSera

Partner Descriptions

AVEO Pharmaceuticals, Inc., an LG Chem company (AVEO), is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.

Emerging Level IRC Partners

Autolus NuvationBio
Immunocore logo L'Oreal